Entering August 2026, global financial market attention is again focused on Wall Street. In recent years, the answer to "why buy US stocks" was highly convergent: buy tech giants like Nvidia, Microsoft, and Apple to enjoy the excess growth dividends from the AI wave. However, as the 2026 Q2 earnings season peaks, a significant structural market shift is quietly occurring—US earnings growth is diffusing from the concentrated drive of the "Magnificent Seven" to broader sectors within the S&P 500 index. This marks a healthier, more sustainable new phase in the US bull market and provides fresh logical support for global investors to reassess and allocate US assets.

1. Earnings Diffusion Emerges: A Historic Optimization of US Market Structure

Reviewing the 2023-2025 US market, the tech "Magnificent Seven" drove most of the S&P 500's earnings growth and price gains due to their absolute dominance in generative AI. This highly concentrated market structure once sparked broad Wall Street concerns: if tech giants' capex growth slowed or AI monetization missed expectations, the broader market would face sharp corrections. But by mid-2026, fresh earnings data paints a starkly different picture.

Latest research notes from top Wall Street investment banks indicate that in 2026 Q2, beyond IT and communication services, EPS for healthcare, industrials, financials, and even some consumer staples saw unexpected upward revisions. This means US earnings breadth is improving at an unprecedented pace. For investors seeking new answers to "why buy US stocks," earnings diffusion vastly expands the investable target pool, eliminating the need to passively bear the drawdown risks of single-sector high valuations.

This structural optimization results from the resonance of macroeconomic conditions and micro corporate behavior. As the market confirms the US economy can achieve a "no-landing" or "soft landing," capital naturally takes partial profits from historically high-valued AI concept stocks, flowing into more attractively valued pro-cyclical sectors sensitive to economic cycles. This is the latest 2026 manifestation of classic US sector rotation logic.

2. Macroeconomic Resilience Supports: Earnings Repair Logic for Pro-Cyclical Sectors

To deeply understand the underlying logic of current US sector rotation, we must return to macro fundamentals. In H2 2026, the US economy shows surprising resilience. The lagged impact of high rates on the real economy, once widely feared, hasn't materialized en masse. Instead, as the Fed signals a clearer rate normalization path, corporate financing costs marginally improve, and manufacturing reshoring and infrastructure investment dividends continue to release.

Specifically, the industrial sector's rise epitomizes this earnings diffusion. Benefiting from the ongoing impact of industrial policies like the CHIPS Act and Inflation Reduction Act, domestic advanced manufacturing construction spending remains high. Many industrial giants raised full-year capex guidance in recent earnings, with order backlogs hitting multi-year highs. This directly boosts industrial profit margins and drives a comprehensive recovery in upstream/downstream chains like raw materials and logistics.

Meanwhile, the financial sector's 2026 performance is equally notable. As long-term rates stabilize or slightly decline, while bank net interest margins peak, trading and wealth management fee income rise with the stock market's wealth effect. Additionally, commercial real estate risks were orderly resolved in 2026, with regulatory stress tests showing major institutions have ample capital buffers. The financial sector's low valuation plus marginal fundamental improvement makes it a preferred "safe haven" for global long-term funds returning to US markets.

3. Healthcare Defensive Value Highlights: Counter-Cyclical Attributes Plus Innovation Catalysts

In the earnings diffusion landscape, healthcare's performance is striking. As a traditional defensive sector, healthcare hit a dual inflection point in fundamentals and tech innovation in 2026. The irreversible global aging trend ensures stable cash flows, while AI's deep application in drug discovery drastically shortens new drug launch cycles and cuts R&D costs.

In 2026 Q2, many multinational pharma and biotech firms reported pipeline progress exceeding expectations. Compared to tech stocks' forward P/E ratios often exceeding 30x, healthcare's overall valuation remains near its historical center of 18x-22x, offering extreme value. For asset-safety-focused global allocation funds, buying US healthcare now hedges tech volatility portfolio risks while sharing biotech innovation alpha. This provides a hardcore reason for "why buy US stocks" based on both defense and growth.

4. Global Capital Rebalancing: Why is Now the Strategic Window for US Allocation?

Standing in August 2026, the global asset allocation landscape is profoundly reshaping. Europe's economy recovers slowly amid structural bottlenecks, while emerging markets face dual tests of geopolitical fragmentation and a strong dollar cycle. In contrast, with its unparalleled market depth, liquidity, transparency, and continuous innovation, the US market remains an irreplaceable core ballast for global capital.

The current US earnings diffusion trend significantly guides global investors' allocation strategies. First, investors can build a risk-diversified, multi-source portfolio via US ETFs or selected sector leaders. No longer must they make difficult "single-choice" bets on whether AI will continue surging; instead, by buying the broader US market, they share the holistic dividends of America's moderate economic expansion.

Second, sector rotation offers active investors rich alpha opportunities. As market sentiment shifts from an extremely concentrated "AI one-sided market" to "multi-point blooming," the seesaw effect of capital among tech, financials, industrials, and healthcare grows obvious. Astute investors can dynamically adjust sector weights across phases by tracking macro indicators and Fed policy paths, achieving buy-low-sell-high.

5. Investment Risk Warnings and Beginner's Guide: Rationally Viewing Hidden Reefs in Diffusion

While earnings diffusion injects new vitality into US markets, mature investors must clearly recognize US investment risks alongside understanding "why buy US stocks." First, inflation's "last mile" remains uncertain. If commodity prices fluctuate in H2, causing core inflation to rebound, the Fed's rate-cut pace could be disrupted, hitting pro-cyclical sectors' valuation repairs.

Second, though the tech "Magnificent Seven's" growth slows, their massive market caps mean a technical correction could still drag down broader indices. When building portfolios, investors must guard against concentration risks from distorted index weights. For beginners, dollar-cost averaging broad index funds (like S&P 500 ETFs) supplemented by sector thematic ETFs as satellite allocations is a good US market entry strategy balancing stability and aggression.

Furthermore, 2026 is a policy implementation period post-US election. Fiscal spending structure tweaks and international trade relation shifts could be black swans triggering short-term volatility in specific sectors. Thus, adhering to fundamental research and avoiding blindly chasing hotspots remains the long-term winning rule for US investing.

Conclusion: Earnings Diffusion Solidifies the Cornerstone of the Long US Bull Market

In summary, the US earnings diffusion in August 2026 results from the combined effects of macroeconomic resilience, industrial policy guidance, and tech innovation spillovers. It breaks the market's path dependency on a few tech giants over the past two years, proving US economic vitality exists not just in Silicon Valley's code, but is rooted in traditional industrial machinery roars and medical lab test tubes.

For global investors, allocating US stocks now is no longer just buying a ticket to an AI future, but buying an equity voucher to share America's comprehensive recovery and deep transformation. Amid intensifying sector rotation and expanding earnings breadth, deeply understanding US multi-layered investment logic and grasping diversified allocation's value will be core to achieving robust returns in H2 and beyond. This is the most compelling contemporary answer to "why buy US stocks" at this juncture.